NYSE:DGX Quest Diagnostics (DGX) Stock Price, News & Analysis $153.66 -0.24 (-0.16%) (As of 08/27/2024 ET) Add Compare Share Share Today's Range$152.97▼$154.5250-Day Range$136.64▼$153.9252-Week Range$119.59▼$154.71Volume494,545 shsAverage Volume966,621 shsMarket Capitalization$17.07 billionP/E Ratio20.68Dividend Yield1.95%Price Target$151.42 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Quest Diagnostics alerts: Email Address Quest Diagnostics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside1.5% Downside$151.42 Price TargetShort InterestHealthy2.52% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainability-0.62Upright™ Environmental ScoreNews Sentiment0.85Based on 14 Articles This WeekInsider TradingSelling Shares$60,094 Sold Last QuarterProj. Earnings Growth7.65%From $8.89 to $9.57 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.87 out of 5 starsMedical Sector27th out of 921 stocksMedical Laboratories Industry1st out of 17 stocks 2.2 Analyst's Opinion Consensus RatingQuest Diagnostics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 4 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageQuest Diagnostics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Quest Diagnostics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.52% of the float of Quest Diagnostics has been sold short.Short Interest Ratio / Days to CoverQuest Diagnostics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quest Diagnostics has recently increased by 19.74%, indicating that investor sentiment is decreasing significantly. Previous Next 4.2 Dividend Strength Dividend YieldQuest Diagnostics pays a meaningful dividend of 1.96%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthQuest Diagnostics has been increasing its dividend for 13 years.Dividend CoverageThe dividend payout ratio of Quest Diagnostics is 40.38%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 31.35% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.Read more about Quest Diagnostics' dividend. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreQuest Diagnostics has received a 74.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private clinical drug testing", "Private genetic testing services", and "Private oncology diagnostics services" products. See details.Environmental SustainabilityThe Environmental Impact score for Quest Diagnostics is -0.62. Previous Next 3.3 News and Social Media Coverage News SentimentQuest Diagnostics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Quest Diagnostics this week, compared to 9 articles on an average week.Search Interest3 people have searched for DGX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,094.00 in company stock.Percentage Held by InsidersOnly 0.79% of the stock of Quest Diagnostics is held by insiders.Percentage Held by Institutions88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Quest Diagnostics' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Quest Diagnostics are expected to grow by 7.65% in the coming year, from $8.89 to $9.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quest Diagnostics is 20.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 146.24.Price to Earnings Ratio vs. SectorThe P/E ratio of Quest Diagnostics is 20.68, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 141.59.Price to Earnings Growth RatioQuest Diagnostics has a PEG Ratio of 2.69. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioQuest Diagnostics has a P/B Ratio of 2.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Quest Diagnostics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Investors Alley140% Yields From Stocks Like Tesla? Here's How (Labor Day Special)Imagine getting a 140% dividend from your investments. And for Labor Day weekend...I'm sharing this secret for just $9.Click here to unlock before this offer expires About Quest Diagnostics Stock (NYSE:DGX)Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Read More DGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DGX Stock News HeadlinesAugust 27 at 3:32 PM | markets.businessinsider.comBarclays Remains a Hold on Quest Diagnostics (DGX)August 26 at 8:50 AM | prnewswire.comQuest Diagnostics Completes Acquisition of LifeLabs, Enhancing Access to Diagnostic InnovationAugust 28, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningIn July 2022, the Biden administration quietly changed the definition of a recession. What followed was an 8-month recession in the stock market.August 21, 2024 | markets.businessinsider.comQuest Diagnostics To Buy University Hospitals' Outreach Laboratory ServicesAugust 21, 2024 | prnewswire.comQuest Diagnostics to Acquire University Hospitals' Outreach Laboratory Services BusinessAugust 19, 2024 | americanbankingnews.comQuest Diagnostics (NYSE:DGX) Reaches New 52-Week High at $152.81August 15, 2024 | prnewswire.comQuest Diagnostics Prices $1.85 Billion of Senior NotesAugust 15, 2024 | prnewswire.comquesthealth.com Introduces 13 New Blood Tests to Identify Micronutrient DeficienciesAugust 28, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningIn July 2022, the Biden administration quietly changed the definition of a recession. What followed was an 8-month recession in the stock market.August 14, 2024 | prnewswire.comQuest Diagnostics Declares Quarterly Cash DividendAugust 13, 2024 | finance.yahoo.comQuest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its ReturnsAugust 12, 2024 | prnewswire.comPregnant Women Undertested for STIs, Finds Quest Diagnostics Health Trends® Study of Over 4 Million PregnanciesAugust 1, 2024 | prnewswire.comQuest Diagnostics Named a "Best Place to Work for Disability Inclusion" for Seventh Straight YearAugust 1, 2024 | marketwatch.comQuest Diagnostics Inc. stock underperforms Tuesday when compared to competitors despite daily gainsJuly 30, 2024 | markets.businessinsider.comQuest Diagnostics: Strong Performance and Growth Trajectory Justify Buy RatingJuly 29, 2024 | marketwatch.comQuest Diagnostics Inc. stock underperforms Monday when compared to competitorsJuly 29, 2024 | prnewswire.comHaystack Oncology and Université de Montréal's affiliated hospital research centre, the CRCHUM, to Deploy Haystack MRD™ Technology in Research Study for Metastatic Colorectal CancerJuly 28, 2024 | seekingalpha.comQuest Diagnostics: Beat Down After Beating Q2 EstimatesSee More Headlines Receive DGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 7/22 Dividend7/08/2024Dividend Payable7/22/2024Last Earnings7/23/2024Today8/27/2024Ex-Dividend for 10/21 Dividend10/04/2024Dividend Payable10/21/2024Next Earnings (Estimated)10/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical laboratories Sub-IndustryHealth Care Services Current SymbolNYSE:DGX CUSIP74834L10 CIK1022079 Webwww.questdiagnostics.com Phone(973) 520-2700Fax201-462-4169Employees48,000Year Founded1967Price Target and Rating Average Stock Price Target$151.42 High Stock Price Target$165.00 Low Stock Price Target$130.00 Potential Upside/Downside-1.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)$7.43 Trailing P/E Ratio20.68 Forward P/E Ratio17.28 P/E Growth2.69Net Income$854 million Net Margins8.99% Pretax Margin11.94% Return on Equity15.35% Return on Assets7.19% Debt Debt-to-Equity Ratio0.57 Current Ratio1.00 Quick Ratio0.91 Sales & Book Value Annual Sales$9.35 billion Price / Sales1.83 Cash Flow$13.26 per share Price / Cash Flow11.59 Book Value$59.79 per share Price / Book2.57Miscellaneous Outstanding Shares111,092,000Free Float110,214,000Market Cap$17.07 billion OptionableOptionable Beta0.89 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. James E. Davis (Age 61)Chairman, CEO & President Comp: $2.88MMr. Sam A. Samad (Age 54)Executive VP & CFO Comp: $1.33MMr. Michael E. Prevoznik (Age 62)Senior VP & General Counsel Comp: $881.23kMs. Catherine T. Doherty (Age 61)Executive Vice President of Regional Businesses Comp: $1MMr. Karthik Kuppusamy Ph.D. (Age 54)Senior Vice President of Clinical Solutions Comp: $840.3kMr. Michael J. Deppe (Age 57)Senior VP, Corporate Controller & Chief Accounting Officer Mr. Murali BalakumarSenior VP, Chief Information & Digital OfficerMr. Shawn C. BevecVice President of Investor RelationsMs. Kristin Lee Wallace Esq.Senior VP & Chief Compliance OfficerMr. Gary D. SamuelsSenior VP & Chief Communications OfficerMore ExecutivesKey CompetitorsLaboratory Co. of AmericaNYSE:LHDaVitaNYSE:DVAChemedNYSE:CHER1 RCMNASDAQ:RCMCorVelNASDAQ:CRVLView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckySold 249 shares on 8/26/2024Ownership: 0.008%Cetera Investment AdvisersBought 243 shares on 8/22/2024Ownership: 0.015%Truist Financial CorpSold 1,372 shares on 8/21/2024Ownership: 0.017%Brandes Investment Partners LPBought 2,320 shares on 8/19/2024Ownership: 0.007%EP Wealth Advisors LLCSold 92 shares on 8/19/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions DGX Stock Analysis - Frequently Asked Questions How have DGX shares performed this year? Quest Diagnostics' stock was trading at $137.88 at the beginning of 2024. Since then, DGX stock has increased by 11.4% and is now trading at $153.66. View the best growth stocks for 2024 here. How were Quest Diagnostics' earnings last quarter? Quest Diagnostics Incorporated (NYSE:DGX) posted its quarterly earnings results on Tuesday, July, 23rd. The medical research company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.31 by $0.04. The company's revenue was up 2.5% on a year-over-year basis. Read the conference call transcript. How will Quest Diagnostics' stock buyback program work? Quest Diagnostics' Board of Directors approved a stock buyback plan on Thursday, February 2nd 2023, which authorizes the company to buy back $1,000,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 6% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's leadership believes its stock is undervalued. What is Steve Rusckowski's approval rating as Quest Diagnostics' CEO? 1,053 employees have rated Quest Diagnostics Chief Executive Officer Steve Rusckowski on Glassdoor.com. Steve Rusckowski has an approval rating of 78% among the company's employees. Does Quest Diagnostics have any subsidiaries? The following companies are subsidiaries of Quest Diagnostics: MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and more. Who are Quest Diagnostics' major shareholders? Top institutional shareholders of Quest Diagnostics include Victory Capital Management Inc. (3.49%), American Century Companies Inc. (2.57%), Davis Selected Advisers (2.15%) and Dimensional Fund Advisors LP (1.90%). Insiders that own company stock include Stephen H Rusckowski, Catherine T Doherty, Michael E Prevoznik, Michael J Deppe, Timothy M Ring, Vicky B Gregg, Karthik Kuppusamy and Mark E Delaney. View institutional ownership trends. How do I buy shares of Quest Diagnostics? Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Quest Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE) and Abbott Laboratories (ABT). This page (NYSE:DGX) was last updated on 8/28/2024 by MarketBeat.com Staff From Our PartnersThese 3 Tech Billionaires Are Prepared for a Radical New Money System. Are You?Ultra-Capitalism is Coming A revolutionary new technological breakthrough is about to ignite a new era of w...Banyan Hill Publishing | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quest Diagnostics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Quest Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DGX Stock Alerts